twistbioscience.com - הכנסה לפני ניכוי ריבית, מסים ופחת TWST
Geopolitical fractures and sanctions are hindering the export of Twist Bioscience (TWST) equipment, slowing down scientific research. However, absolute EBITDA is growing due to the implementation of unique silicon-based DNA printing and a strategic alliance with Big Pharma for antibody development. This chart indicates capacity expansion, while the 0.00 metric serves as the target level for current operating profit.
פילוחי נתונים אנליטיים מרוכזים עבור Twist Bioscience, Inc. (TWST)
The indicator is calculated as earnings before interest, taxes, depreciation, and amortization, reflecting the net cash flow from core operations. This metric measures the internal efficiency of the business, excluding the impact of debt load and accounting write-offs. For Twist Bioscience (TWST), growth in this value confirms the high profitability of robotic synthetic DNA production. However, the EBITDA trajectory often becomes a point of conflict between buyer optimism and seller concerns. The resulting price action determines the company's future cost of capital.
